All Oncology News

Studies in pancreatic and prostate cancer selected for ASCO’s Plenary Program.

Neil D. Gross, MD, FACS, discusses how anti–PD-1 therapy is changing treatment approaches in advanced CSCC.

The European Medicines Agency’s CHMP has issued a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in first-line BRAF V600E–mutant mCRC.

The CHMP granted a positive opinion to perioperative pembrolizumab/enfortumab vedotin as well as pembrolizumab and berahyaluronidase alfa in MIBC.

Bispecific antibodies and the latest proton therapy techniques are taking center stage in the treatment of patients with head and neck cancers.

The FDA has published new sets of product-specific guidelines for investigating generic cancer treatments to guide proper evaluation of bioequivalence.

The University of Texas MD Anderson Cancer Center announced that Albert Koong, MD, PhD, has been appointed chief scientific officer.

Marwan G. Fakih, MD, outlines situations when ctDNA and tissue NGS agree, when they diverge, and scenarios that should prompt repeat liquid biopsy testing.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Yelena Novik, MD, notes the use of CDK4/6 inhibitors in ER-positive breast cancer and the role of oral SERDs in the management of select metastatic cases.

Gerald Soff, MD, discusses how romiplostim could improve long-term outcomes in patients with GI cancer and thrombocytopenia by preserving relative dose intensity.

CHMP recommends camizestrant plus CDK4/6 inhibitor for ESR1-mutated HR+/HER2– advanced breast cancer, based on SERENA-6 phase 3 trial data.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

Mayo Clinic researchers are advancing brain tumor care through molecular profiling, improved diagnostics for younger patients, new drug delivery methods, and emerging immunotherapies.

Poll results reflected some of the most anticipated presentations and fields of interest in hematologic oncology at the 2026 ASCO Annual Meeting.

Poll results reflect some of the most anticipated presentations and fields of interest in gynecologic oncology at the 2026 ASCO Annual Meeting.

The FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Ahead of the 2026 ASCO Annual Meeting, results from the phase 3 FIGHT-302 study have been announced.

The expansion of the Huntsman Cancer Institute Senator Orrin G. Hatch Proton Therapy Center will significantly increase access to proton therapy.

Biomarker analyses indicate that CD47 expression may help predict benefit from zanidatamab plus evorpacept in HER2-positive metastatic breast cancer.

Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.

Brad Haverkos, MD, discusses how he utilizes mogamulizumab for cutaneous T-cell lymphoma and how to manage rashes associated with the treatment.

Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.

Researchers from Roswell Park led key studies presented at the 2026 AUA Annual Meeting.

A supplemental BLA for nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease is under review by the FDA.

The FDA has granted fast track designation to suplexa in MSI-H CRC.

The FDA granted orphan drug designation to CLN-049 for relapsed or refractory acute myeloid leukemia based on data from early-phase studies.

Researchers found that macrophages are associated with response to chemotherapy before treatment in triple-negative breast cancer.